Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 6;13(2):e0192381.
doi: 10.1371/journal.pone.0192381. eCollection 2018.

Five year outcomes of Boston type I keratoprosthesis as primary versus secondary penetrating corneal procedure in a matched case control study

Affiliations

Five year outcomes of Boston type I keratoprosthesis as primary versus secondary penetrating corneal procedure in a matched case control study

Kai B Kang et al. PLoS One. .

Abstract

Despite improved retention and reduced complication rates paving the way for the current expansion of applications and surge in prevalence for the Boston type I Keratoprosthesis (KPro), the most frequent indication for its implantation today remains prior graft failure. The purpose of this study is to evaluate the long-term outcomes of primary KPro and compare to secondary implantation in a matched cohort study. This study included patients who underwent KPro implantation in a single center by two surgeons between July 2008 and October 2014. All eyes with KPro implantation as the primary procedure with a minimum follow up of 12 months were matched with eyes with same preoperative diagnoses that underwent secondary KPro implantation. Main outcomes included visual acuity and device retention. A total of 56 eyes were included with 28 eyes in each group. Mean follow up was 5.0 years for both groups. Twenty-nine percent (8) of the eyes in the primary group had a diagnosis of chemical or thermal injuries, 25% (7) aniridia, 18% (5) autoimmune disease, 4% (1) infectious keratitis/neurotrophic cornea, 7% (2) gelatinous corneal dystrophy, 7% (2) ectrodactyly ectodermal dysplasia/limbal stem cell deficiency, and 11% (3) uveitis/hypotony. Sixty-one percent (17) of the eyes in the primary group and 39% (11) in the secondary group maintained a final best-corrected visual acuity of 20/200 or better at a mean follow up of 5.0 years; the probability of maintaining best-corrected vision is 0.83 and 0.49 for primary and secondary groups at 5.0 years (p = 0.02). There is no statistically significant difference between groups in device retention (p = 0.22) or postoperative complication rates (p >0.05). This study demonstrates that Boston KPro implantation may be successful as a primary procedure in patients at high risk of failure with traditional penetrating keratoplasty. The device has a good long-term retention rate and visual outcomes are promising however a larger study is needed for more definitive results.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Survival of visual acuity.
Graph showing best-corrected visual acuity survival curves for both primary and secondary groups. X-axis demonstrates post-operative months, and y-axis demonstrates survival of best-corrected visual acuity (e.g 1.0 = 100% of the eyes maintaining best-corrected post-operative visual acuity). P-value was calculated using Log-rank test. Table below shows the number of eyes followed at each time point.
Fig 2
Fig 2. Device retention.
Graph showing KPro survival curves for both primary and secondary groups. X-axis demonstrates post-operative months, and y-axis demonstrates KPro survival (e.g. 1.0 = 100% of the eyes with device retention). P-value was calculated using Log-rank test. Table below shows the number of eyes followed at each time point.

Similar articles

Cited by

References

    1. Dohlman CH, Harissi-Dagher M, Khan BF, Sippel K, Aquavella JV, Graney JM. Introduction to the use of the Boston keratoprosthesis. Expert Review of Ophthalmology. 2006. October;1(1):41–8.
    1. Saeed HN, Shanbhag S, Chodosh J. The Boston keratoprosthesis. Curr Opin Ophthalmol. 2017. April 5; - PubMed
    1. Lee WB, Shtein RM, Kaufman SC, Deng SX, Rosenblatt MI. Boston Keratoprosthesis: Outcomes and Complications: A Report by the American Academy of Ophthalmology. Ophthalmology. 2015. July;122(7):1504–11. doi: 10.1016/j.ophtha.2015.03.025 - DOI - PubMed
    1. Zerbe BL, Belin MW, Ciolino JB, Boston Type 1 Keratoprosthesis Study Group. Results from the multicenter Boston Type 1 Keratoprosthesis Study. Ophthalmology. 2006. October;113(10):1779.e1–7. - PubMed
    1. Chew HF, Ayres BD, Hammersmith KM, Rapuano CJ, Laibson PR, Myers JS, et al. Boston keratoprosthesis outcomes and complications. Cornea. 2009. October;28(9):989–96. doi: 10.1097/ICO.0b013e3181a186dc - DOI - PubMed